Alpha Strategic Share Discussion Threads

[rambutan2] 09/10/2006 09:24

hmmm. could be another deal in the pipeline.

[abcd1234] 22/9/2005 10:16

nice chart so far

[cezary] 12/8/2005 20:02

With a mere 3mill shares on float, I am surprised anybody got a look in.
Will try and grab a few myself next week.!!

[abcd1234] 12/8/2005 14:29

the rns above re First Day of Dealing says what they intend to do, and who the mgt are

[2kushax] 12/8/2005 14:22

Quite stunning growth in the last few minutes.

On the monitor

[abcd1234] 12/8/2005 14:14

no current thread on this, so here is a place to post comments if u want to

[roofer2] 04/1/2005 01:19

It is lonely on this page,has anyone got any info/ updates

[currypasty] 20/12/2004 09:44

LSE changed ticker after 1 day trading


Ascribe, the health IT group focusing on medicines management, today announces
the commencement of dealings of its Ordinary Shares on the AIM market (AIM) of
the London Stock Exchange. Seymour Pierce is acting as Nominated Adviser and as
Broker to the Company. The stock market EPIC will be ASP.L.

Placing Statistics
Total number of New Ordinary Shares being placed on behalf of the Company 27,777,778
Number of Sale Shares being placed on behalf of Selling Shareholders 2,777,778
Total number of Ordinary Shares being placed 30,555,556
Issue Price 18p
Number of Ordinary Shares in issue immediately following Admission 103,441,732
Percentage of the Enlarged Share Capital being placed 29.5%
Market capitalisation at the Issue Price #18.6 million
Gross proceeds of the Placing receivable by the Company #5 million


Reasons for Admission to AIM and use of proceeds of the Placing
The proceeds of the Placing of the New Ordinary Shares, expected to amount to #5
million (before expenses) will be used by the Company, amongst other things, to
fund the acquisition of Protechnic Exeter Limited.

Stephen Critchlow, Chairman and Chief Executive of Ascribe, said: "We are
delighted that the flotation of the Company has been completed successfully.
The listing will enable us to take Ascribe to the next stage of its development
and maximise any acquisition opportunities for the Company within the
international healthcare market. Our strategy is to build on our position in
the medicines management market through organic growth and through a number of
acquisitions of profitable companies, such as Protechnic Exeter, which offer
complementary established systems to customers needing a medicines management
solution."